David Altschuler

David Altschuler, the Chief Scientific Officer at Vertex, dives into the pressing issue of sickle cell disease affecting 100,000 Americans. He discusses the company’s strategic focus on targeting this disease and the extensive R&D efforts behind it. The conversation touches on the social implications of sickle cell, particularly the challenges faced by African-American patients in accessing effective treatment. Insights on innovative therapies and the emotional toll on patients highlight the importance of compassionate care and the hope for improved patient outcomes.